Loading...
•
Sep 30, 2022
Palatin Technologies Q1 2023 Earnings Report
Reported financial results for the fiscal first quarter ended September 30, 2022.
Key Takeaways
Palatin Technologies reported a net loss of $8.3 million for the quarter ended September 30, 2022. Net product revenue increased 13% over the prior quarter and 445% over the comparable quarter in 2021. Cash and cash equivalents were $21.2 million as of September 30, 2022.
Vyleesi net product revenue increased 13% and prescriptions dispensed increased 17%, over the prior quarter.
Phase 3 pivotal study of PL9643 in patients with Dry Eye Disease is ongoing.
Phase 2 clinical study of oral PL8177 in patients with Ulcerative Colitis has commenced.
Closed on a $10 Million Registered Direct Offering.
Forward Guidance
Palatin currently expects an operating cash runway through calendar year 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...